Astrogen focus on the R&D of innovative therapies for diseases with significant unmet needs in the CNS field. Its lead program, AST-001, is positioned to potentially become the first-in-disease pharmacological therapy for the core symptoms of autism spectrum disorder (ASD) in the pediatric population. AST-001 received orphan drug designation by the Korea MFDS and has completed a Phase 3 clinical trial in South Korea.